Search clinical trials for: Intermediate syndrome

Total 37974 results

Medical University of Warsaw

Recruiting

Multimodality Imaging and Functional Lesion Assessment in Intermediate Coronary Stenosis in Chronic Coronary Syndrome (MultiInter-CCS)

Chronic Coronary Syndrome

Poland
Natasha Appelman-Dijkstra

Recruiting

DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD) (DeFiD)

Fibrous Dysplasia | McCune Albright Syndrome

Netherlands
Royal Devon and Exeter NHS Foundation Trust
University of Chicago; University of Bergen; University of Rome Tor Vergata

Recruiting

Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome (iDEND)

Epilepsy | Intellectual Disability | ADHD | Neurodevelopmental Disorders | Autism Spectrum Disorder | Development Delay

United States, United Kingdom, Italy, Norway
Indiana University
Congressionally Directed Medical Research Programs; National Intrepid Center...

Recruiting

Building Emotional Self-Awareness Teletherapy (BEST) (BEST)

Concussion, Mild | Concussion, Brain | Concussion, Severe | Concussion, Intermediate | Concussion; Syndrome | Concussion Injury of Cerebrum | Concussion With Brief Loss of Consciousness | Alexithymia

United States
Forma Therapeutics, Inc.

Recruiting

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

United States, France, Canada, Germany
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States, Japan, Argentina, Hong Kong, Greece, Italy, China, Australia, Spain, Austria, Denmark, Germany, Sweden, Switzerland, Canada, Czechia, Korea, Republic of, Poland, Turkey, France
Evangelismos Hospital

Recruiting

Intermediate Normal Versus High Normal Oxygen Levels in the Emergency Department for Severe Traumatic Brain Injury (INACHOS)

Traumatic Brain Injury | Acute Respiratory Distress Syndrome | Acute Respiratory Failure | Acute Brain Injury

Greece
Benha University

Recruiting

Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases

Pars Planitis | Central Serous Chorioretinopathy | Cystoid Macular Edema | Irvine-Gass Syndrome

Egypt
University of Leipzig
Curis, Inc.

Recruiting

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (LUCAS)

Myelodysplastic Syndromes | Anemia

Germany
The First Affiliated Hospital of Soochow University

Recruiting

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

AML | MDS | Old Age; Debility | Hematologic Cancer

China
CytoSorbents Europe GmbH
BRAHMS GmbH; MedInnovation GmbH

Recruiting

A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock (PROCYSS)

Septic Shock

Germany
Karolinska Institutet

Recruiting

Coronary Computed Tomographic Angiography in Intermediate-risk Chest Pain Patients (FAST-CCTA)

Coronary Artery Disease | Chest Pain | Acute Coronary Syndrome

Sweden
Keros Therapeutics, Inc.

Recruiting

A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Cytopenia

Australia, Spain, United States, Israel, France, Germany, New Zealand, Czechia
Peking University People's Hospital

Recruiting

RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT

Myelodysplastic Syndromes

China
BioLite, Inc.

Not yet recruiting

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Aplastic Anemia | de Novo Myelodysplastic Syndrome

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Neoplasms | Myelodysplastic Syndromes | Non-Hodgkin Lymphoma | Solid Tumor, Adult

United States, Spain, Israel, Germany, Canada
Novartis Pharmaceuticals

Active, not recruiting

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (STIMULUS-MDS1)

Myelodysplastic Syndromes

Czechia, Hungary, Japan, Taiwan, United States, Belgium, Italy, United Kingdom, Korea, Republic of, Hong Kong, Austria, Germany, Turkey, Spain, Greece, France, Canada
Shanghai Antengene Corporation Limited

Terminated

A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) (HATCH)

Myelodysplastic Syndrome

China
National Cancer Institute (NCI)

Active, not recruiting

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditions

United States
Geron Corporation

Active, not recruiting

Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States, Canada, Belgium, Spain, Czechia, Korea, Republic of, United Kingdom, Netherlands, Israel, Germany, Russian Federation, Switzerland, Italy, France, Turkey, Poland, Ukraine
NYU Langone Health
Perlmutter Cancer Center

Completed

A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations

Myelodysplastic Syndromes

United States
Karyopharm Therapeutics Inc

Active, not recruiting

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Acute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDS

United States, France, Canada, Spain, China
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

China, Czechia, Japan, Saudi Arabia, Taiwan, Turkey, Germany, Spain, Netherlands, Italy, Singapore, Australia, Austria, France, United Kingdom, Korea, Republic of, Thailand, Israel, Belgium, Canada, Switzerland, Lithuania, Russian Federation and more
Region Skane

Completed

Norepinephrine Administration Through a Midline Catheter in an Intermediate Care Unit

Septic Shock | Hypotension and Shock | Norepinephrine Adverse Reaction

Sweden
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
Longboard Pharmaceuticals

Available

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Dravet Syndrome | Lennox Gastaut Syndrome | Developmental and Epileptic Encephalopathies

United States
Celgene

Completed

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, United Kingdom, Australia, Poland, Spain, Belgium, Italy, Germany, France, Canada
Gesellschaft fur Medizinische Innovation - Hamatologie...
ClinAssess GmbH

Completed

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q (MDS-LE-MON-5)

Myelodysplastic Syndromes

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Leukemia

United States
Vanderbilt University Medical Center
Veloxis Pharmaceuticals

Enrolling by invitation

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

Lung Transplant; Complications

United States
Celgene

Completed

A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea (RevlimidPMS)

Lymphoma, Follicular | Myelodysplastic Syndromes | Lymphoma, Mantle-Cell

Korea, Republic of
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
M.D. Anderson Cancer Center
Incyte Corporation

Completed

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Sumitomo Pharma America, Inc.

Terminated

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Myelodysplastic Syndromes (MDS)

United States
Sumitomo Pharma America, Inc.

Terminated

A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

Anemia in Myelodysplastic Syndromes

United States
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Myelodysplastic Syndromes

China, Japan
Astex Pharmaceuticals, Inc.

Terminated

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Gesellschaft fur Medizinische Innovation - Hamatologie...
Amgen

Completed

Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia (EUROPE)

Myelodysplastic Syndromes

France, Germany
Celgene

Completed

An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

Myelodysplastic Syndromes

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia With Multilineage Dysplasia | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Blasts 20-30 Percent of Peripheral Blood White Cells | IPSS Risk Category Intermediate-2

United States
Bristol-Myers Squibb

Completed

A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) (DIM Vidaza)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

China
Mesoblast International Sàrl

Available

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
Franck Boccara

Completed

French CAC-HIV Cohort Study (CAC-HIV)

HIV Infections | Coronary Artery Calcification
Northwell Health
Toshiba America Medical Systems, Inc.

Enrolling by invitation

The Value of CT-FFR Compared to CCTA or CCTA and Stress MPI in Low to Intermediate Risk ED Patients With Toshiba CT-FFR

Coronary Artery Disease | Chest Pain | Acute Coronary Syndrome | Acute Myocardial Infarction

United States
Stealth BioTherapeutics Inc.

Available

An Intermediate Size Expanded Access Protocol of Elamipretide

Mitochondrial Diseases | Barth Syndrome
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | IPSS Risk Category Intermediate-1

United States
Janssen Research & Development, LLC

Completed

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Myelodysplastic Syndromes

United States, Belgium, Italy, Spain, Netherlands, Russian Federation
Amgen

Completed

Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS
Hope Biosciences Stem Cell Research Foundation
Hope Biosciences

No longer available

Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome

Post COVID-19 Syndrome

United States

Search clinical trials for: Intermediate syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations